Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

Recruiting

Phase 3

Sacituzumab Govitecan vs. Standard of CareStudy of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

Sponsor:

Gilead Sciences

Code:

NCT06801834

Conditions

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Sacituzumab Govitecan (SG)

Topotecan

Amrubicin (Japan only)

Lurbinectedin (regions/countries where approved and available)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-06-04. This information was provided to ClinicalTrials.gov by Gilead Sciences on 2026-05-20.